News AbbVie signs $225m 'immunoneurology' deal to tackle Alzheime... Partnership will use novel approach to treating Alzheimer's.
News Intellia files CRISPR drug after historic phase 3 readout Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
